Media Coverage

A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer’s disease (AD) is likely not the cause of patients’ mild cognitive impairment, finds a new study published in Frontiers in Neurology by researchers from Quest Diagnostics, the University of Florida and Mount Sinai Medical Center in Miami Beach.

Precision medicine in rheumatoid arthritis expanded in a small but key measure late last year, when Quest Diagnostics and Scipher Medicine announced a partnership to provide RNA extraction and sequencing services for the latter’s PrismRA test.

Quest Diagnostics Health Trends topics are selected with expectations that reports may reveal important new novel public health insights. We collaborate with national academic experts and leaders in public health on many of our studies. To find impactful findings, this external input helps shape the objectives and study designs. Many of our studies have been highlighted by premier news outlets, nationally and regionally, and have been integrated into professional guidelines.

Quest Diagnostics on Tuesday announced a new tool available to dermatologists for making treatment decisions for patients with melanoma. The gene expression test, MelaNodal Predict, is based on technology developed by the oncology biotechnology company SkylineDx and researchers at Mayo Clinic.

Years of exposure to nonstick cookware, fast-food packaging, fire-fighting gear and water-resistant household products have resulted in increased levels of PFAS, also known as "forever chemicals," in practically every American's bloodstream. Quest Diagnostics announced Monday the first "consumer-initiated, physician-ordered blood-draw test for PFAS chemicals." The test, which you order online, will be available from most of Quest's approximately 2,100 diagnostic centers in the country and will include (if desired) a separate telephone consultation with a licensed physician to go over the results and ways to reduce the exposure risk.

Suhash Harwani, Ph.D, Senior Director of Science & Technology for Employer Solutions at Quest Diagnostics, shares drug positivity and testing options that employers should know about.

On Jan. 31, Fortune released its World's Most Admired Companies list, which included healthcare companies. The list, a partnership between Fortune and global management consulting firm Korn Ferry, follows an examination of about 1,500 candidates: the 1,000 largest U.S. companies ranked by revenue, along with non-U.S. companies in Fortune's Global 500 database that have revenues of $10 billion or more.

Just as users around the world are surely strapping on new Fitbits with an aim of tackling health-focused New Year’s resolutions, so too is Fitbit itself kicking off 2024 with its sights set on a new goal. The Google-owned fitness tracker maker is teaming up with Quest Diagnostics, according to a Wednesday release, to study how the combination of the two companies’ products could potentially help improve metabolic health, which is linked to conditions like diabetes, heart disease and stroke.

Quest Diagnostics has acquired select assets of outreach laboratory services in Pennsylvania and Ohio from Steward Health Care System, a large, private, and fully-integrated for-profit system based in Dallas. In addition, subject to transfer of the laboratory license, Quest has also acquired certain assets from the laboratory business serving Hawthorn Medical Associates in Dartmouth, MA.

Haystack Oncology said on Monday that it has struck a deal to investigate the use of its minimal residual disease (MRD) testing technology in non-small cell lung cancer (NSCLC) in collaboration with research organization Alliance Foundation Trials (AFT).

Quest Diagnostics and Scipher Medicine announced a collaboration designed to expand patient access to diagnostic services for rheumatoid arthritis. Under a multiyear collaboration, Quest will provide RNA extraction and next-generation sequencing services for Scipher’s PrismRA test, a blood-based molecular signature response classifier aimed at predicting a patient’s response to TNF inhibitor therapy.

Quest Diagnostics unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives.

On this episode I talked to Michael Racke, MD Medical Director of Neurology at Quest Diagnostics. Michael discusses promising advancements in our understanding and treatment of Alzheimer’s disease. He explains how imaging and biomarkers have allowed earlier and more accurate diagnosis, moving from just a clinical picture to actually visualizing amyloid plaques and tau tangles in the brain.

Quest Diagnostics said Thursday that its Haystack Oncology subsidiary has entered a collaboration agreement with Rutgers Cancer Institute of New Jersey for a study of early-stage triple-negative breast cancer patients. Researchers will use Haystack's MRD technology to help evaluate therapeutic response and collect molecular information on individuals undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.

Secaucus-based Quest Diagnostics on Thursday said it was awarded a contract by the Centers for Disease Control and Prevention designed to assess the burden of hepatitis C virus in the U.S. The agreement marks a new phase of a decadelong collaboration between Quest and the CDC to improve hepatitis public health research based on insights from laboratory data.

Four local students from two academic institutions have been selected to participate in the American Heart Association’s Historically Black Colleges and Universities (HBCU) Scholars program, which is designed to help address racial disparity among medical students and physicians. According to the Association of American Medical Colleges, only eight percent of medical students and five percent of physicians are Black and African American. The program is funded by a grant provided by the Quest Diagnostics Foundation, which also supports the American Heart Association’s Hispanic Serving Institutes (HSI) Scholars Program.

Scipher Medicine and Quest Diagnostics have announced a multiyear collaboration to expand access to diagnostic services for patients with rheumatoid arthritis (RA).

Quest Diagnostics is teaming up with a Spain-based biotech to bring an advanced colorectal cancer screening blood test to the U.S. Under the new partnership, the Secaucus-headquartered testing provider will work with UDX to develop and seek U.S. Food and Drug Administration premarket approval for a novel “liquid biopsy” blood test to screen for colorectal cancer, the third leading cause of cancer death in the country, according to a Nov. 20 announcement.

For its third annual look-ahead, CLP recently asked a wide range of clinical laboratory experts to look into their professional crystal balls and make their predictions for 2024.

In honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.

Quest Diagnostics recently launched Quest Mobile™, which the Secaucus-based health care company says will make it easier and more convenient for patients to have a specimen collected for lab testing nationwide. Patients can request an appointment for at-home specimen collection with a trained Quest Mobile phlebotomist for a broad range of laboratory tests in the comfort of their home.

Michael McPhaul, MD, is senior medical director of endocrinology at Quest Diagnostics and editor of the Journal of Investigative Medicine High Impact Case Reports. His work at Quest Diagnostics focuses on the development of new tests for biomarkers of metabolic health to improve prevention, early diagnosis, and monitoring for patients with cardiometabolic health conditions. Here, he discusses advances in insulin resistance testing.

Alzheimer's disease is the most common form of dementia and affecting about 6 million people in the United States. A simple blood test is providing a new way for doctors to detect the potential risk of Alzheimer's disease in its early stages. Here to talk about this groundbreaking new approach is a board-certified neurologist and medical director of neurology at Quest Diagnostics.

Diagnostics firm Diadem said Wednesday that it has licensed exclusive US rights to its AlzoSure Predict Alzheimer's blood test to Quest Diagnostics. Under the agreement, Quest can develop, validate, and market the assay, which is intended to identify individuals likely to progress to Alzheimer's disease, as a laboratory-developed test in the US. AlzoSure Predict measures a variant of the p53 protein that has been linked to Alzheimer's disease.

Laboratory operator Quest Diagnostics on Tuesday raised its full-year sales forecast after beating third-quarter expectations for revenue and profit, buoyed by a recovery in routine testing. The company raised its full-year net sales forecast to $9.19 billion to $9.24 billion, from its previous expectations of $9.12 billion to $9.22 billion. Sales from Quest's base business, which includes a range of diagnostic tests for allergies, chronic diseases and cancer, rose 4.6% to $2.27 billion in the third quarter. That extends a rebound in routine health check-ups delayed due to pandemic-related lockdowns for diagnostic firms like Quest and eases the blow from plunging demand for COVID-19 tests.